Systems biology driven tissue engineering

系统生物学驱动的组织工程

• 批准号: 293170-2011
• 负责人: Stanford, William
• 金额: $ 3.5万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=571406
• 关键词: Systems; biology; driven; tissue; engineering

Arthritis disables more than 4 million Canadians, causing pain, limiting the quality of life, and having a major impact on health care costs ($4.4 billion/yr in Canada as of 2000) Current treatments involve analgesics to reduce pain, and in severe cases, load-bearing joints such as hips and knees are replaced. Unfortunately, these artificial implants often fail because the material used to make them is incompatible with our bodies. What is needed is either better drug therapies for patients to regrow cartilage or the development of biological joints (knees and hips, etc). Our project is designed to understand the development of cartilage cells (the cells of the joint) from two potential replacement cell sources (pluripotent stem cells and mesenchymal stromal cells) and then improve on the differentiation of these cells into cartilage tissue. To do this, we will develop networks (essentially roadmaps) of how these stem cells differentiate into cartilage and other cells and then manipulate the differentiation cultures to improve conditions to convert the stem cells into joint cartilage. Along the way, we should identify drug pathways that will be used in the future to screen for drugs that will be used to replace cartilage in arthritis patients.

关节炎使超过400万加拿大人致残，引起疼痛，限制生活质量，并对医疗保健费用产生重大影响（截至2000年，加拿大每年44亿美元）目前的治疗方法包括止痛剂以减轻疼痛，在严重的情况下，髋关节和膝关节等承重关节被替换。不幸的是，这些人工植入物经常失败，因为用于制造它们的材料与我们的身体不相容。我们需要的是更好的药物治疗，让患者再生软骨或生物关节（膝盖和臀部等）的发展。 我们的项目旨在了解软骨细胞（关节细胞）从两种潜在的替代细胞来源（多能干细胞和间充质基质细胞）的发育，然后改善这些细胞分化为软骨组织。为此，我们将开发这些干细胞如何分化为软骨和其他细胞的网络（基本上是路线图），然后操纵分化培养物以改善将干细胞转化为关节软骨的条件。沿着这条路，我们应该确定药物途径，这些药物途径将在未来用于筛选用于替代关节炎患者软骨的药物。